Gilead to Test Inhaled Form of Remdesivir in COVID-19 Starting in August

Currently, the only drug approved for use against COVID-19 is Gilead Sciences’ remdesivir. The antiviral drug is given to patients intravenously via daily infusions at the hospital. In an open letter from the company’s chairman and chief executive officer, Daniel O’Day reported that the U.S. Food and Drug Administration (FDA) had given the company approval to begin clinical trials of an inhaled version of the drug.